Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer.

Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer.
复制标题

靶向雷帕霉素的哺乳动物靶标(MTOR):一种治疗癌症的新方法。

DOI:
10.1038/sj.bjc.6602162
复制
发表时间:
2004-10-18
影响因子:
8.8
通讯作者:
Chan, S
Chan, S
中科院分区:
医学1区
文献类型:
--
作者:
Chan, S

文献摘要

参考文献

被引文献

相似文献

mTOR是PI3K/Akt信号通路的下游介质,在调节细胞基本功能中起关键作用。这些包括细胞增殖、存活、移动和血管生成。雷帕霉素及其类似物(CCI-779、RAD001和AP23573)对mTOR的功能具有特异性拮抗作用。这导致下游信号元件的抑制,并导致细胞周期在G1期停滞。这组药物可能在肿瘤治疗中占有一席之地,这些癌症是由于PI3激酶/Akt/m-TOR通路活性增加而发生的。本文综述了mTOR通路的基本结构以及靶向mTOR治疗癌症的临床研究结果。这是一个令人兴奋的发展领域,对研究人员提出了许多挑战。
mTOR is a downstream mediator in the PI3K/Akt signalling pathway, which plays a critical role in regulating basic cellular functions. These include cell proliferation, survival, mobility and angiogenesis. Rapamycin and its analogues (CCI-779, RAD001 and AP23573) have specific antagonistic action on the function of mTOR. This leads to inhibition of the downstream signalling elements and results in the cell cycle arrest in the G1 phase. This group of drugs may have a place in Oncology for the treatment of cancers, which occur as a result of increased activity of the PI3 kinase/Akt/m-TOR pathway. The basic structure of the pathway was reviewed in this article, together with results of the clinical studies targeting mTOR for cancer therapy. This is an exciting area for development and poses many challenges to researchers.
DOI: 10.1073/pnas.95.13.7772
发表时间: 1998-06-23
影响因子: 11.1
作者:
Scott, PH;Brunn, GJ;Lawrence, JC
通讯作者: Lawrence, JC
DOI: 10.1038/369756a0
发表时间: 1994-06-30
期刊: NATURE
影响因子: 64.8
作者:
BROWN, EJ;ALBERS, MW;SCHREIBER, SL
通讯作者: SCHREIBER, SL
DOI: 10.1101/gad.12.4.502
发表时间: 1998-02-15
影响因子: 10.5
作者:
Gingras, AC;Kennedy, SG;Hay, N
通讯作者: Hay, N
DOI: 10.1210/endo-128-4-2045
发表时间: 1991-04-01
期刊: ENDOCRINOLOGY
影响因子: 4.8
作者:
ARONICA, SM;KATZENELLENBOGEN, BS
通讯作者: KATZENELLENBOGEN, BS
DOI: 10.1074/jbc.m010840200
发表时间: 2001-03-30
影响因子: 4.8
作者:
Campbell, RA;Bhat-Nakshatri, P;Nakshatri, H
通讯作者: Nakshatri, H